0001209191-20-045930.txt : 20200810
0001209191-20-045930.hdr.sgml : 20200810
20200810161355
ACCESSION NUMBER: 0001209191-20-045930
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200806
FILED AS OF DATE: 20200810
DATE AS OF CHANGE: 20200810
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ALTSHULER DAVID
CENTRAL INDEX KEY: 0001550395
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19319
FILM NUMBER: 201089522
MAIL ADDRESS:
STREET 1: C/O VERTEX PHARMACEUTICALS INCORPORATED
STREET 2: 130 WAVERLY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA
CENTRAL INDEX KEY: 0000875320
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043039129
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 6173416393
MAIL ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-08-06
0
0000875320
VERTEX PHARMACEUTICALS INC / MA
VRTX
0001550395
ALTSHULER DAVID
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON
MA
02210
0
1
0
0
EVP, Global Research and CSO
Common Stock
2020-08-06
4
M
0
1223
155.57
A
30125
D
Common Stock
2020-08-06
4
S
0
490
270.12
D
29635
D
Common Stock
2020-08-06
4
S
0
423
271.39
D
29212
D
Common Stock
2020-08-06
4
S
0
310
272.60
D
28902
D
Stock Option (Right to Buy)
155.57
2020-08-06
4
M
0
1223
0.00
D
2028-02-05
Common Stock
1223
7338
D
Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1.
Open market sales reported on this line occurred at a weighted average price of $270.12 (range $269.73 to $270.58).
Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Open market sales reported on this line occurred at a weighted average price of $271.39 (range $270.94 to $271.89).
Open market sales reported on this line occurred at a weighted average price of $272.60 (range $272.35 to $272.88).
The option vests in 16 quarterly installments from 02/06/2018.
/s/ Sabrina Yohai, Attorney-in-Fact
2020-08-10